Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 3/20 | 0.82 |
| ▸ | POLB | P06746 | 2/20 | 0.82 |
| ▸ | GBA1 | P04062 | 1/20 | 0.82 |
| ▸ | PDE5A | O76074 | 2/20 | 0.77 |
| ▸ | KDM1A | O60341 | 1/20 | 0.76 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.72 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.72 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.72 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12316824 | 0.90 | GAA (1.00) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL1063103 | 0.89 | ABCG2 (1.00) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL4868573 | 0.88 | ABCG2 (1.00) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL2294276 | 0.88 | ABCG2 (0.78) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL15452480 | 0.87 | MEN1 (1.00) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL14262835 | 0.86 | ABCG2 (0.82) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL13945468 | 0.85 | ABCG2 (1.00) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL8095812 | 0.85 | ABCG2 (1.00) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL4867505 | 0.85 | ABCG2 (1.00) | ABCG2MEN1KMT2AGAAMAPT | |
| SCHEMBL1058652 | 0.84 | ABCG2 (1.00) | ABCG2MEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | claimed |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED | 2014-01-30 | — | — | US | claimed |
| EP-2651405-A2 | CASEIN KINASE 1 (CK1 ) INHIBITORS | Electrophoretics Limited (GB) | 2013-10-23 | — | — | EP | claimed |
| WO-2012080729-A2 | CASEIN KINASE 1δ (CK1δ) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2012-06-21 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| US-20200078387-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
| WO-2018112342-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED | 2014-01-30 | — | — | US | disclosed |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED | 2014-01-30 | — | — | US | disclosed |
| EP-2651405-A2 | CASEIN KINASE 1 (CK1 ) INHIBITORS | Electrophoretics Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2007092537-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1G3 | ABCG2 4649/4885MEN1 3661/4885KMT2A 1033/4885 |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, IDE, CTSC | ABCG2 713/4885MEN1 3779/4885KMT2A 4519/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | ABCG2 4161/4885MEN1 3510/4885KMT2A 810/4885 |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, EPOR, HBB | ABCG2 336/4885MEN1 3792/4885KMT2A 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.